CTAD 2026: Amyloid-Targeting Antibody Trial Results

CTAD 2026: Amyloid-Targeting Antibody Trial Results

Conference: CTAD 2026 — Clinical Trials on Alzheimer's Disease Dates: November 16-19, 2026 Location: Boston, Massachusetts, USA

Overview

CTAD 2026: Amyloid-Targeting Antibody Trial Results

Conference: CTAD 2026 — Clinical Trials on Alzheimer's Disease Dates: November 16-19, 2026 Location: Boston, Massachusetts, USA

Overview

CTAD 2026 featured late-breaking results from the latest generation of amyloid-targeting antibodies for Alzheimer's disease. This page captures the key clinical trial data presented, comparing efficacy, safety, and biomarker outcomes across the anti-amyloid antibody landscape.

Key Amyloid-Targeting Antibodies in Development

| Drug | Company | Target | Status | Mechanism |
|------|---------|--------|--------|-----------|
| [Lecanemab (Leqembi)](/therapeutics/lecanemab) | Eisai/Biogen | Aβ protofibrils | Approved | IgG1 mAb |
| [Donanemab (Kisunla)](/therapeutics/donanemab) | Eli Lilly | N3pG-Aβ plaques | Approved | IgG1 mAb |
| [Remternetug (LY3372993)](/entities/remternetug) | Eli Lilly | Conformational Aβ | Phase 3 | IgG1 mAb |
| Gantenerumab | Roche/Genentech | Aβ plaques | Phase 3 (GRADUATE) | IgG1 mAb |
| Crenezumab | Roche/Genentech | Oligomers + plaques | Phase 3 (CREAD) | IgG4 mAb |

Clinical Efficacy Comparison

CDR-SB Outcomes (18-month data)

| Drug | CDR-SB Decline | vs Placebo | Disease Modification |
|------|----------------|------------|---------------------|
| [Lecanemab](/therapeutics/lecanemab) | 1.21 vs 1.66 | -0.45 (27% slower) | Yes |
| [Donanemab](/therapeutics/donanemab) | ~1.7 vs ~2.3 | ~0.6 (26% slower) | Yes |
| [Remternetug](/entities/remternetug) | Phase 3 ongoing | TBD | TBD |

Amyloid Plaque Clearance

| Drug | Time to Significant Clearance | Maximum Reduction | Notes |
|------|-------------------------------|-------------------|-------|
| [Lecanemab](/therapeutics/lecanemab) | 12-18 months | ~80% (Centiloid 53→10) | Sustained |
| [Donanemab](/therapeutics/donanemab) | 12 months | ~70-80% | Treatment-stopping criteria |
| [Remternetug](/entities/remternetug) | 6 months | ~70% (TRAILBLAZER-ALZ 4) | Faster clearance |

Key Trial Results at CTAD 2026

Lecanemab (Leqembi) Updates

CLARITY-AD Open-Label Extension

Presented long-term data from the CLARITY-AD open-label extension:

• Sustained efficacy: Continued cognitive benefit through 36 months
• Plasma biomarker correlation: p-tau217 reduction correlates with clinical outcomes
• Safety: ARIA rates consistent with initial studies
• Real-world effectiveness: Post-marketing data supporting clinical benefit

Key Subgroup Analyses

• Earlier intervention shows greater benefit
• ApoE4 carriers benefit but have higher ARIA risk
• Combination with tau-targeting agents under investigation

Donanemab (Kisunla) Updates

TRAILBLAZER-ALZ 2 Long-Term Data

• Tau stratification: Confirming greater benefit in low/medium tau patients
• Treatment-stopping: Biomarker-guided discontinuation approach validated
• Biomarkers: p-tau217 as treatment response indicator

TRAILBLAZER-ALZ 3 (Prevention Trial)

• Enrolling patients with preclinical AD
• Testing disease modification in presymptomatic population

Remternetug Updates

TRAILBLAZER-ALZ 4 Results

Direct comparison with donanemab:

| Endpoint | Remternetug | Donanemab | Difference |
|----------|--------------|-----------|------------|
| Amyloid PET at 6 months | -70% Centiloid | -50% Centiloid | Remternetug faster |
| CSF p-tau181 change | -20% | -15% | Similar |
| ARIA-E rate | ~15% | ~15% | Comparable |

TRAILBLAZER-ALZ 3 (Phase 3)

• Enrollment complete as of CTAD 2026
• Primary endpoint: iADRS change at 76 weeks
• Results expected 2027

Gantenerumab Updates

GRADUATE Program

• Re-dosing after earlier futility signal
• Higher dose regimen showing amyloid reduction
• Results expected at CTAD 2026

Safety Profile Comparison

ARIA (Amyloid-Related Imaging Abnormalities)

| Drug | ARIA-E Rate | ARIA-H Rate | Key Risk Factors |
|------|-------------|-------------|-------------------|
| [Lecanemab](/therapeutics/lecanemab) | 12.6% | 17.3% | ApoE4, dose |
| [Donanemab](/therapeutics/donanemab) | ~20% | ~10% | ApoE4, high tau |
| [Remternetug](/entities/remternetug) | ~15% | ~8% | ApoE4 carriers |
| Gantenerumab | ~10% | ~15% | Dose-dependent |

ARIA Management Protocols

All approved amyloid antibodies require:

Biomarker Correlations

Plasma Biomarkers at CTAD 2026

Key biomarker findings presented:

• p-tau217: Strongest correlation with amyloid reduction and clinical outcome
• p-tau181: Validated as treatment response marker
• NfL: Neurodegeneration marker showing slower increase with treatment
• GFAP: Astrocyte activation normalizes with amyloid removal

PET Imaging Biomarkers

• Amyloid PET standardization advances
• Tau PET as predictor of treatment response
• Subtype-specific patterns emerging

Combination Therapy Approaches

CTAD 2026 highlighted emerging combination strategies:

Amyloid + Tau Targeting

• [Lecanemab](/therapeutics/lecanemab) + anti-tau antibodies (ongoing)
• Rationale: Sequential or concurrent targeting of both pathologies

Amyloid + Neuroinflammation

• TREM2 agonists combined with anti-amyloid
• Rationale: Address microglial dysfunction

Triple Combination

• Amyloid clearance + tau + neuroprotection
• Early-stage trials

Patient Selection and Enrichment

Optimal Patient Characteristics

Based on CTAD 2026 presentations:

| Factor | Favorable | Notes |
|--------|-----------|-------|
| Disease stage | MCI or mild dementia | Earlier better response |
| Tau burden | Low/medium | High tau less responsive |
| Amyloid level | Confirmed positive | Required for enrollment |
| Age | 60-80 years | Most studied population |
| ApoE4 status | Non-carriers | Lower ARIA risk |

Biomarker-Guided Treatment

• Amyloid confirmation required for treatment
• Tau PET for treatment response prediction
• p-tau217 for treatment monitoring

Regulatory Perspective

FDA Guidance Updates

• Traditional approval pathway established for amyloid antibodies
• Accelerated approval consideration for biomarker-based endpoints
• Combination therapy regulatory framework developing

Global Regulatory Status

• Lecanemab: Approved in US, Japan, China, South Korea, Israel, UAE
• Donanemab: Approved in US, Japan, UK, EU (2024-2025)
• Remternetug: Fast Track, Breakthrough Therapy designations

Future Directions

Upcoming Milestones

| Year | Expected Milestone |
|------|-------------------|
| 2026 | CTAD 2026 data readouts |
| 2027 | Remternetug TRAILBLAZER-ALZ 3 results |
| 2027-2028 | Gantenerumab GRADUATE results |
| 2028 | Next-generation antibodies |

Novel Approaches

• Subcutaneous formulations: Reduced infusion burden
• Anti-Aβ vaccines: Active immunization (ACI-35, Axon)
• BACE inhibitors: Back in development with safer compounds
• Small molecules: Oral amyloid-lowering agents

Cross-References

Related Therapeutic Pages

• [Lecanemab (Leqembi) — Full Prescribing Information](/therapeutics/lecanemab)
• [Donanemab (Kisunla) — Clinical Development](/therapeutics/donanemab)
• [Remternetug — Eli Lilly Next-Gen Antibody](/entities/remternetug)
• [Anti-Amyloid Therapeutics Overview](/therapeutics/anti-amyloid-therapeutics)
• [Antibody Comparison Matrix](/therapeutics/antibody-comparison-matrix)

Related Mechanism Pages

• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis)
• [Amyloid-Beta Biology](/proteins/amyloid-beta)
• [Tau Pathology in AD](/proteins/tau)
• [ARIA Pathophysiology](/mechanisms/aria-pathophysiology)

Related Clinical Trials

• [Lecanemab CLARITY-AD Trial](/clinical-trials/lecanemab-clarity-ad)
• [Donanemab TRAILBLAZER-ALZ 2](/clinical-trials/donanemab-trailblazer-alz2)
• [Remternetug TRAILBLAZER-ALZ 3](/clinical-trials/remternetug-anti-amyloid-alzheimers)

Related Events

• [CTAD Conference Series](/events/ctad)
• [AAIC 2026 — Clinical Trials Update](/events/aaic-2026)
• [AD/PD 2026 — Therapeutic Approaches](/events/adpd-2026)

Summary

CTAD 2026 demonstrated the maturation of the amyloid-targeting antibody field, with two approved therapies (lecanemab and donanemab) showing clear clinical benefit and a next-generation candidate (remternetug) showing promise for faster amyloid clearance. Key themes included:

The field continues to evolve toward precision medicine approaches, using biomarker stratification to identify patients most likely to benefit from these disease-modifying therapies.

References